Cell penetrating peptides in the delivery of biopharmaceuticals

Biomolecules

Volumn 2, Issue 2, 2012, Pages 187-202

  Munyendo, Were L L ^a   Lv, Huixia ^a   Benza Ingoula, Habiba ^b   Baraza, Lilechi D ^c   Zhou, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^c MASINDE MULIRO UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Kenya)

Author keywords

Carriers; Cell penetrating peptides; Drug delivery; Oligoarginines

Indexed keywords

AMINOCAPROIC ACID; CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DELCASERTIB; DRUG CARRIER; PENETRATIN; PSORBAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO ACID SUBSTITUTION; ANTISENSE THERAPY; CATION; CELL MEMBRANE; CELL SPECIFICITY; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; GENE TARGETING; HUMAN; NONHUMAN; PROTEIN MODIFICATION; PSORIASIS; REVIEW;

EID: 85016359924     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom2020187     Document Type: Review

References (72)

1. De Coupade, C.; Fittipaldi, A.; Chagnas, V.; Michel, M.; Carlier, S.; Tasciotti, E.; Darmon, A.; Ravel, D.; Kearsey, J.; Giacca, M.; Cailler, F. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem. J. 2005, 390, 407-418.
2. Veerle, K.; Cornelissen, B. Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals 2010, 3, 600-620.
3. Nathan, S.; Abhijit, M.; Ghee, H.L.; Gerard, W.C.L. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010, 3, 1806-1813.
4. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157, 195-206.
5. Deshayes, S.; Morris, M.C.; Divita, G.; Heitz, F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 2005, 62, 1839-1849.
6. Snyder, E.L.; Dowdy, S.F. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin. Drug Deliv. 2005, 2, 43-51.
7. Fisher, L.; Soomets, U.; Cortés Toro, V.; Chilton, L.; Jiang, Y.; Langel, U.; Iverfeldt, K. Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Ther. 2004, 11, 1264-1272.
8. Zatsepin, T.S.; Turner, J.J.; Oretskaya, T.S.; Gait, M.J. Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing. Curr. Pharm. Des. 2005, 11, 3639-3654.
9. Pujals, S.; Fernandez-Carneado, J.; Lopez-Iglesias, C.; Kogan, M.J.; Giralt, E. Mechanistic aspects of CPP-mediated intracellular drug delivery: Relevance of CPP self-assembly. Biochim. Biophys. Acta 2006, 1758, 264-279.
10. El-Andaloussi, S.; Holm, T.; Langel, Ü. Cell-penetrating peptides: Mechanism and applications. Curr. Pharm. Des. 2005, 11, 3597-3611.
11. Murriel, C.L.; Dowdy, S.F. Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin. Drug Deliv. 2006, 3, 739-746.
12. Schwarze, S.R.; Hruska, K.A.; Dowdy, S.F. Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol. 2000, 10, 290-295.
13. Abes, S.; Turner, J.; Ivanova, G.D.; Owen, D.; Williams, D.; Arzumanov, A. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res. 2007, 35, 4495-4502.
14. Meade, B.R.; Dowdy, S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 2007, 59, 134-140.
15. Morris, M.C.; Deshayes, S.; Heitz, F.; Divita, G. Cell-penetrating peptides: From molecular mechanisms to therapeutics. Biol. Cell 2008, 100, 201-217.
16. Gros, E.; Deshayes, S.; Morris, M.C.; Aldrian-Herrada, G.; Depollier, J.; Heitz, F. A non-covalent peptide-based strategy for protein Peptide-based drug delivery technology and peptide nucleic acid delivery. Biochim. Biophys. Acta 2006, 1758, 384-393.
17. Munoz-Morris, M.A.; Heitz, F.; Divita, G.; Morris, M.C. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem. Biophys. Res. Commun. 2007, 355, 877-882.
18. Langel, U. Handbook of Cell-Penetrating Peptides; Taylor & Francis Group, LLC: Boca Raton, FL, USA, 2006.
19. Kaeko, K.; Hiroshi, N.; Shusei, U.; Akiyoshi, F. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications. Int. J. Mol. Med. 2010, 25, 41-51.
20. Torchilin, V.P. Cell penetrating peptide-Modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers (Pept. Sci.) 2008, 90, 604-610.
21. Trabulo, S.; Cardoso, A.L.; Mano, M.; de Lima, M.C.P. Cell-penetrating peptides-Mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 2010, 3, 961-993.
22. Glover, D.J.; Lipps, H.J.; Jans, D.A. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005, 6, 299-310.
23. Kilk, K.; El-Andaloussi, S.; Järver, P.; Meikas, A.; Valkna, A.; Bartfai, T. Evaluation of Transportan 10 in PEI mediated plasmid delivery assay. J. Control. Release 2005, 103, 511-523.
24. Martin, M.E.; Rice, K.G. Peptide-guided gene delivery. AAPS J. 2007, 9, E18-E29.
25. Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 2009, 61, 704-709.
26. Kim, W.J.; Christensen, L.V.; Jo, S.; Yockman, J.W.; Jeong, J.H.; Kim, Y.H. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 2006, 14, 343-350.
27. Crombez, L.; Charnet, A.; Morris, M.C.; Aldrian-Herrada, G.; Heitz, F.; Divita, G. A non-covalent peptide-based strategy for siRNA delivery. Biochem. Soc. Trans. 2007, 35, 44-46.
28. Nguyen, Q.N.; Chavli, R.V.; Marques, J.T., Jr.; Conrad, P.G.; Wang, D.; He, W. Light controllable siRNAs regulate gene suppression and phenotypes in cells. Biochim. Biophys. Acta 2006, 1758, 394-403.
29. Zeineddine, D.; Papadimou, E.; Chebli, K.; Gineste, M.; Liu, J.; Grey, C. Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev. Cell 2006, 11, 535-546.
30. Kumar, P.; Wu, H.; McBride, J.L.; Jung, K.E.; Kim, M.H.; Davidson, B.L. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 7149, 39-43.
31. Ezzat, K.; Andaloussi, S.E.L.; Zaghloul, E.M.; Lehto, T.; Lindberg, S.; Moreno, P.M.D.; Viola, J.R.; Magdy, T.; Abdo, R.; Guterstam, P.; Sillard, R.; Hammond, S.M.; Wood, M.J.A.; Arzumanov, A.A.; Gait, M.J.; Smith, C.I.E.; Hällbrink, M.; Langel, Ü. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res. 2011, 39, 5284-5298.
32. Lebleu, B.; Moulton, H.M.; Abes, R.; Ivanova, G.D.; Abes, S.; Stein, D.A.; Iversen, P.L.; Arzumanov, A.A.; Gait, M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 2008, 60, 517-529.
33. Laufer, S.D.; Recke, A.L.; Veldhoen, S.; Trampe, A.; Restle, T. Noncovalent peptide-mediated delivery of chemically modified steric block oligonucleotides promotes splice correction: Quantitative analysis of uptake and biological effect. Oligonucleotides 2009, 19, 63-80.
34. Oehlke, J.; Wallukat, G.; Wolf, Y.; Ehrlich, A.; Wiesner, B.; Berger, H.; Bienert, M. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur. J. Biochem. 2004, 271, 3043-3049.
35. Abes, S.; Williams, D.; Prevot, P.; Thierry, A.; Gait, M.J.; Lebleu, B. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J. Control. Release 2006, 110, 595-604.
36. Shiraishi, T.; Pankratova, S.; Nielsen, P.E. Calcium ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic TAT and oligoarginine peptides. Chem. Biol. 2005, 12, 923-929.
37. Wolf, Y.; Pritz, S.; Abes, S.; Bienert, M.; Lebleu, B.; Oehlke, J. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry 2006, 45, 14944-14954.
38. Eguchi, A.; Dowdy, S.F. siRNA delivery using peptide transduction domains. Trends Pharmacol. Sci. 2009, 30, 341-345.
39. Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 2009, 61, 704-709.
40. Deshayes, S.; Morris, M.; Heitz, F.; Divita, G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev. 2008, 60, 537-547.
41. Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999, 285, 1569-1572.
42. Tan, M.L.; Choong, P.F.; Dass, C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2009, 31, 184-193.
43. Clayton, R.; Ohagen, A.; Nicol, F.; Del Vecchio, A.M.; Jonckers, T.H.M.; Goethals, O.; van Loock, M.; Michiels, L.; Grigsby, J.; Xu, Z.; Zhang, Y.P.; Gutshall, L.L.; Cunningham, M.; Jiang, H.; Bola, S.; Sarisky, R.T.; Hertogs, K. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antivir. Res. 2009, 84, 142-149.
44. McCarthy, J.R.; Weissleder, R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 2008, 60, 1241-1251.
45. Koch, A.M.; Reynolds, F.; Merkle, H.P.; Weissleder, R.; Josephson, L. Transport of surface-modified nanoparticles through cell monolayers. Chembiochem 2005, 6, 337-345.
46. Lee, H.; Jefferies, R.; Watt, P.; Hopkins, R.; Sotzik, F.; Reid, S.; Armson, A.; Boxell, A.; Ryan, U. In vitro analysis of the TAT protein transduction domain as a drug delivery vehicle in protozoan parasites. Exp. Parasitol. 2008, 118, 303-307.
47. Bian, J.; Popovic, Z.B.; Benejam, C.; Kiedrowski, M.; Rodriguez, L.L.; Penn, M.S. Effect of cellbased intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ. Res. 2007, 100, 1626-1633.
48. Marcella, F.; Farzin, F.; Nagy, H.; Farooq, M.; Joop, G.; Mahvash, T. Delivery of therapeutic proteins as secretable TAT fusion products. Mol. Ther. 2009, 17, 334-342.
49. Mino, T.; Mori, T.; Aoyama, Y.; Sera, T. Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. Arch. Virol. 2008, 153, 1291-1298.
50. de Coupade, C.; Fittipaldi, A.; Chagnas, V.; Michel, M.; Carlier, S.; Tasciotti, E.; Darmon, A.; Ravel, D.; Kearsey, J.; Giacca, M.; Cailler, F. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem. J. 2005, 390, 407-418.
51. Harrison, S.D.; Chen, L. Cell-penetrating peptides in drug development: Enabling intracellular targets. Biochemical Society Transactions 2007, 35, 821-825.
52. Jearawiriyapaisarn, N.; Moulton, H.M.; Buckley, B.; Roberts, J.; Sazani, P.; Fucharoen, S.; Iversen, P.L.; Kole, R. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 2008, 16, 1624-1629.
53. Sarko, D.; Beijer, B.; Garcia Boy, R.; Nothelfer, E.M.; Leotta, K.; Eisenhut, M.; Altmann, A.; Haberkorn, U.; Mier, W. The pharmacokinetics of cell-penetrating peptides. Mol. Pharm. 2010, 7, 2224-2231.
54. Martín, I.; Teixidó, M.; Giralt, E. Building cell selectivity into CPP-mediated strategies. Pharmaceuticals 2010, 3, 1456-1490.
55. Chen, L.; Harrison, S.D. Cell-penetrating peptides in drug development: Enabling intracellular targets. Biochem. Soc. Trans. 2007, 35, 821-825.
56. Lebleu, B.; Moulton, H.M.; Abes, R.; Ivanova, G.D.; Abes, S.; Stein, D.A.; Iversen, P.L.; Arzumanov, A.A.; Gait, M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 2008, 60, 517-529.
57. Sebbage, V. Cell-penetrating peptides and their therapeutic applications. Biosci. Horiz. 2009, 2, 64-72.
58. Juliano, R.L.; Alam, R.; Dixit, V.; Kang, H.M. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 324-335.
59. Summerton, J.E. Morpholino, siRNA, and S-DNA compared: Impact of structure and mechanism of action on off-target effects and sequence specificity. Curr. Top. Med. Chem. 2007, 7, 651-660.
60. Stein, D.A. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr. Pharm. Des. 2008, 14, 2619-2634.
61. Moulton, J.D.; Jiang, S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 2009, 14, 1304-1323.
62. Swenson, D.L.; Warfield, K.L.; Warren, T.K.; Lovejoy, C.; Hassinger, J.N.; Ruthel, G.; Blouch, R.E.; Moulton, H.M.; Weller, D.D.; Iversen, P.L.; Bavari, S. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 2009, 53, 2089-2099.
63. Tripathi, S.; Chaubey, B.; Barton, B.E.; Pandey, V.N. Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome. Virology 2007, 363, 91-103.
64. Ganguly, S.; Chaubey, B.; Tripathi, S.; Upadhyay, A.; Neti, P.; Howell, R.W.; Pandey, V.N. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 2008, 18, 277-286.
65. Amand, H.L.; Fant, K.; Nordén, B.; Esbjörner, E.K. Stimulated endocytosis in Penetratin uptake: Effect of arginine and lysine. Biochem. Biophys. Res. Commun. 2008, 371, 621-625.
66. Mason, A.J.; Leborgne, C.; Moulay, G.; Martinez, A.; Danos, O.; Bechinger, B. Optimising histidine rich peptides for efficient DNA delivery in the presence of serum. J. Contr. Rel. 2007, 118, 95-104.
67. Henriques, S.T.; Castanho, M.A. Translocation or membrane disintegration? Implication of peptide-membrane interactions in pep-1 activity. J. Pept. Sci. 2008, 14, 482-487.
68. Fei, L.; Zaro, J.; Shen, W.-C. Acid-labile Modification of a Cell Penetrating Peptide for Use in Targeted Drug Delivery. Contributed Papers: Drug Delivery Biopharmaceutics/Other,/AAPS2009-002238. University of Southern California, Los Angeles, CA, USA, 10 November 2009. Available online: http://www.aapsj.org/abstracts/AM (accessed on 01 October 2012).
69. Veerle, K.; Cornelissen, B. Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals 2010, 3, 600-620.
70. Delcroix, M.; Riley, L.W. Cell-penetrating peptides for antiviral drug development. Pharmaceuticals 2010, 3, 448-470.
71. Gupta, B.; Levchenko, T.S.; Torchilin, V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57, 637-651.
72. Mäe, M.; Myrberg, H.; El-Andaloussi, S.; Langel, Ü. Design of a tumor homing cell-penetrating peptide for drug delivery. Int. J. Pept. Res. Ther. 2009, 15, 11-15.